截止 1月23日当周处方量突破2.6万个 ，口服司美格鲁肽片成为诺和诺德在 2026开年彰显其在糖尿病和肥胖症领域主导地位的代表之作。 在刚刚结束的 2026年JPM医疗健康大会上，诺和诺德并未回避竞争日益加剧的国际市场，反而 释放 出一个 强 有力的 信号： GLP-1 赛道 的下半场， 将由 口服制剂 主导 。 诺和诺德的战略方向正转向主动收缩与聚焦。公司计划在 2026年将业务重新集中至糖尿病与肥胖症两大核心领域，从而结束此前相对分散的业务布局。 此外，该公司预测口服减重药未来将占据重要市场份额，超过三分之一的肥胖患者可能倾向于选择此类疗法，而非传统的注射制剂。 此次战略回归的核心，正是全球首款 口服 大分子药物 ——口服司美格鲁肽片。该药于年初刚刚在美国上市，商品名为 Wegovy Pill 。 1月5日 一经上 市，便迅速成为当地肥胖症市场的明星产品， 处方量从首四天的 3,071个跃升至截至1月16日当周的逾18,000个，并于截至1月23日当周进一步达到 26,109个，展现强劲上市势头 。 口服多肽曾被视为制药界的 "圣杯"。这在科学上极难实现，胃肠道是生物进化的杰作，专门用来防御外来蛋白。胃 ...

Core Insights - A recent study by the Chinese Center for Disease Control and Prevention highlights the alarming economic burden of diabetes in China, projecting that by 2030, costs related to diabetes could reach $460 billion, accounting for one-third of the national public health expenditure in 2024 [1] - The study indicates that the direct medical costs associated with diabetes are only a fraction of the total burden, with complications leading to increased hospitalization, productivity loss, and indirect costs [1] Group 1: Treatment Paradigm Evolution - Over the past 30 years, the treatment philosophy and technology for diabetes in China have undergone significant changes due to the growing patient population and disease burden [2] - The evolution of diabetes medications has transitioned from traditional drugs to insulin therapies and newer glucose-lowering agents, with a focus on addressing complex pathophysiological mechanisms [2] - Recent advancements include SGLT2 inhibitors and GLP-1 receptor agonists, which not only lower blood sugar but also show potential cardiovascular protection and reduced kidney disease risk [2] Group 2: Shift Towards Personalized Treatment - There is a growing recognition among endocrinologists that solely targeting blood sugar levels is insufficient for addressing metabolic disorders in patients [3] - The focus of diabetes management is shifting towards metabolic syndrome management through precision medicine and multi-target drug development [3] - The demand for more convenient and quality-of-life-enhancing administration methods is increasing, leading to a trend towards oral medications [3] Group 3: Breakthroughs in Oral Drug Delivery - Oral medications are preferred for their ease of use, but the delivery of large-molecule drugs has been challenging due to their physicochemical properties [4] - Innovations in drug delivery systems, such as Emisphere's Eligen technology and MYCAPSSA, aim to overcome barriers to oral absorption of large molecules [4] - Novo Nordisk's development of SNAC as an absorption enhancer for oral semaglutide represents a significant breakthrough in the field [5][6] Group 4: Comprehensive Metabolic Benefits - GLP-1 receptor agonists provide multiple therapeutic benefits beyond glucose control, including weight loss, improved lipid profiles, and cardiovascular and renal protection [7][8] - Clinical trials have demonstrated that oral semaglutide significantly reduces HbA1c levels and body weight while also lowering blood pressure and improving lipid levels [8] - The recent SOUL trial results indicate that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14%, with even higher reductions in specific populations [8] Group 5: Innovative Payment Models - The introduction of innovative payment systems is essential for improving access to oral glucose-lowering medications and reducing the economic burden on patients and society [10] - The "Xinxiang Care" patient support program aims to alleviate medication costs and enhance treatment accessibility for type 2 diabetes patients [10] Group 6: Future of Diabetes Treatment - The emergence of oral GLP-1 receptor agonists marks a new era in diabetes treatment, integrating treatment into daily life and enhancing patient experience [11] - Oral semaglutide is the first and currently the only oral GLP-1 receptor agonist proven to have cardiovascular benefits, indicating a shift in chronic disease management [12]